Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | SNCA | P37840 | 5/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.48 |
| ▸ | APP | P05067 | 5/20 | 0.47 |
| ▸ | HNF4A | P41235 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2270275 | 1.00 | PKM (0.54) | PKMKMT2AMEN1MAPTGRIK1 | |
| SCHEMBL2276655 | 0.87 | PKM (0.62) | PKMKMT2AMEN1MAPTGRIK1 | |
| SCHEMBL2276651 | 0.87 | PKM (0.62) | PKMKMT2AMEN1MAPTGRIK1 | |
| SCHEMBL2271439 | 0.86 | MEN1 (0.52) | PKMKMT2AMEN1MAPTGRIK1 | |
| SCHEMBL2271435 | 0.86 | MEN1 (0.52) | PKMKMT2AMEN1MAPTGRIK1 | |
| SCHEMBL2270230 | 0.86 | KMT2A (0.57) | PKMKMT2AMEN1MAPTGRIK1 | |
| SCHEMBL2270237 | 0.86 | KMT2A (0.57) | PKMKMT2AMEN1MAPTGRIK1 | |
| SCHEMBL2268347 | 0.84 | SNCA (0.48) | PKMKMT2AMEN1MAPTGRIK1 | |
| SCHEMBL2268352 | 0.84 | SNCA (0.48) | PKMKMT2AMEN1MAPTGRIK1 | |
| SCHEMBL2278462 | 0.84 | MEN1 (0.56) | PKMKMT2AMEN1MAPTGRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101094829-B | novel anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO.,LTD. (JP) | 2012-02-08 | — | — | CN | disclosed |
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| CN-101094829-A | Novel anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO LTD (JP) | 2007-12-26 | — | — | CN | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | PKM 2367/4885KMT2A 1669/4885MEN1 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.